Body mass index and prognosis of breast cancer

Sun, Li; Zhu, Yuan Xiao; Qian, Qi; Tang, Liming

doi:10.1097/md.0000000000011220

Cited by 64 publications

(44 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zaid et al [19] published a metaanalysis with 2,267 patients and found increased overall mortality with an HR of 2.37 (95%CI 2.03, 2.87 p < 0.001) for the no-CM group compared with those who underwent CM. Sun et al [20] recently reported a large analysis including 6,994 patients with mRCC, of which 28% underwent metastasectomy at some point of their disease. They found increase survival for the CM subgroup (HR 0.83 95%CI 0.77-0.90 p < 0.001).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model

Fares

Araújo

Calsavara

et al. 2019

ecancer

View full text Add to dashboard Cite

Introduction: We evaluated overall survival (OS) benefit of complete metastasectomy (CM) in metastatic renal cell carcinoma (mRCC) using a propensity score-matched (PSM) analysis to balance groups by age, gender and by the International Metastatic RCC Database Consortium prognostic model (IMDC). Methods: We included patients (pts) treated at the AC Camargo Cancer Center between 2007 and 2016. Pairs were matched by age, gender and IMDC. Kaplan-Meier survival estimates and Cox proportional hazard models were used to evaluate OS on CM and no-CM group. Results: We found 116 pts with clear cell mRCC. After PSM, the number was reduced to 74 (37 CM, 37 no-CM). The median OS for CM and no-CM was 98.3 months and 40.5 months, respectively (hazard ratio 0.24 95%CI 0.11-0.53 p < 0.001). The OS benefit of CM was confirmed on favourable and intermediate IMDC but was absent on poor IMDC. The CM group received less systemic therapy than the no-CM group. Ten pts in the CM group still have no evidence of disease (NED). Conclusion: After matching for age, gender and IMDC, we found CM impacts on OS and also diminishes the need for systemic treatment. Survival benefit was confirmed for favourable/intermediate IMDC but not for the poor IMDC prognostic model. Further studies correlating IMDC and metastasectomy are needed to guide clinical decision-making.

show abstract

Section: Discussionmentioning

confidence: 99%

“…They found increase survival for the CM subgroup (HR 0.83 95%CI 0.77-0.90 p < 0.001). However, both Zaid et al [19] and Sun [20] et al did not specify types of systemic treatment nor site of metastasectomy. They also did not have available IMDC risk factor data and is possible that groups are not well-balanced by these prognostic variables.…”

Section: Discussionmentioning

confidence: 99%

Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model

Fares

Araújo

Calsavara

et al. 2019

ecancer

View full text Add to dashboard Cite

show abstract

“…While some studies indicate the positive relationship between BMI and BC risk, the others showed an inverse correlation. [39][40][41][42] However, the molecular mechanism of the association between obesity and BC is not completely understood, which could be due to the fact that various factors such as age, menopausal status and environmental factors have major impacts on study findings. 43 Additionally, gene expression of omentin-1 and its serum levels were significantly higher in grade I compared to grade II and III (P = 0.001, P < 0.0001, respectively) as shown in Table 3.…”

Section: Association Of Omentin-1 Gene Expression and Its Serum Levelmentioning

confidence: 99%

Association of Omentin-1 with Oxidative Stress and Clinical Significances in Patients with Breast Cancer

et al. 2019

View full text Add to dashboard Cite

Purpose: Breast cancer (BC) is globally the main reason of cancer-related deaths in women. Omentin-1, an anti-inflammatory and antioxidant adipokine, plays different roles in tumorigenesis and anti-oncogenic pathways. In present study, we investigated the association of omentin-1 with oxidative stress and clinical significances in healthy controls and BC patients to assess the prognostic and diagnostic value of omentin-1 in this cancer. Methods: This case-control study included 88 BC patients and 86 healthy controls. The serum levels of omentin-1 were assessed by enzyme-linked immunosorbent assays methods. Also, total antioxidant capacity (TAC), total oxidant status (TOS) and malondialdehyde (MDA) serum levels were measured by spectrophotometer. quantitative real-time polymerase chain reaction (qRT-PCR) was applied to the measurement of gene expression of omentin-1. Results: the serum levels of omentin-1 were significantly lower in the BC patients compared to the healthy controls (P<0.001). Moreover, gene expression of omentin-1was significantly downregulated in the BC tissues compared to the adjacent normal tissues (P<0.001). Gene expression of omentin-1and its serum levels were significantly higher in grade I compared with grade II and III (P=0.001, P<0.001, respectively). Additionally, the serum levels of omentin-1 in the p53-positive BC patients were significantly higher than the p53-negative BC patients (P=0.001). There was an inverse correlation between the serum levels of MDA and TOS with the serum levels of omentin-1 (r=-0.436, r=-461, respectively). Conclusion: We conclude that omentin-1 may have a good prognostic and diagnostic roles in the BC patients and decreases oxidative stress in these patients.

show abstract

“…Obesity is a known risk factor for various health disorders, including breast cancer (BC). 1 Obesity is generally evaluated using body mass index (BMI), that is an indirect measurement of adipose tissue, calculated as weight in kilograms divided height in meters squared. BMI cannot account for differences in fat distribution and cannot distinguish between adipose tissue and muscles.…”

Section: Introductionmentioning

confidence: 99%

<p>Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy</p>

Omarini¹,

Palumbo

Pecchi³

et al. 2019

CMAR

View full text Add to dashboard Cite

Background: Fat tissue is strongly involved in BC tumorigenesis inducing insulin resistance, chronic inflammation and hormonal changes. Computed tomography (CT) imaging instead of body mass index (BMI) gives a reliable measure of skeletal muscle mass and body fat distribution. The impact of body composition parameters (BCPs) on chemosensitivity is still debated. We examined the associations between BCPs and tumor response to neoadjuvant chemotherapy (NC) in patients treated for operable breast cancer (BC). Methods: A retrospective review of BC patients treated with NC in Modena Cancer Center between 2005 and 2017 was performed. BCPs, such as subcutaneous fat area (SFA), visceral fat area (VFA), lumbar skeletal muscle index (LSMI) and liver-to-spleen (L/S) ratio were calculated by Advance workstation (General Electric), software ADW server 3.2 or 4.7. BMI and BCPs were correlated with pathological complete response (pCR) and survival outcomes. Results: 407 patients were included in the study: 55% with BMI < 25 and 45% with BMI ≥ 25. 137 of them had pre-treatment CT scan imagines. Overweight was significantly associated with postmenopausal status and older age. Hormonal receptor positive BC was more frequent in overweight patients (p<0.05). Postmenopausal women had higher VFA, fatty liver disease and obesity compared to premenopausal patients. No association between BMI classes and tumor response was detected. High VFA and liver steatosis were negative predictive factors for pCR (pCR rate: 36% normal VFA vs 20% high VFA, p= 0.048; no steatosis 32% vs steatosis 13%, p=0.056). Neither BMI classes nor BCPs significantly influenced overall survival and relapse-free survival. Conclusion: Visceral adiposity as well as steatosis were closely involved in chemosensitivity in BC patients treated with NC. Their measures from clinically acquired CT scans provide significant predictive information that outperform BMI value. More research is required to evaluate the relationship among adiposity site and survival outcomes.

show abstract

Body mass index and prognosis of breast cancer

Cited by 64 publications

References 39 publications

Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model

Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model

Association of Omentin-1 with Oxidative Stress and Clinical Significances in Patients with Breast Cancer

<p>Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy</p>

Contact Info

Product

Resources

About